Cordycepin targets integrin, focal adhesion kinase (FAK), c-Jun N-terminal kinases (JNK), PI3K/Akt/mammalian target of rapamycin (mTOR), nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), IL-6, IL-1β, TNF-α, extracellular-signal-regulated kinase (ERK), Fas, B-cell lymphoma-2 (Bcl-2), caspase, and C-X-C motif chemokine receptor (CXCR) 4 cascades, thereby leading to the repression of angiogenesis, metastasis, EMT, proliferation, viability, and invasion of LC cells [147–153]. The gene discussed is BCL2; the disease is laryngotracheoesophageal cleft.